Pictet Asset Management
CORT icon

Pictet Asset Management’s Corcept Therapeutics CORT Stock Holding History

Pictet Asset Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.29M Sell
14,812
-877
-6% -$53K ﹤0.01% 1053
2026
Q1 		$632K Buy
15,689
+1,309
+9% +$48.9K ﹤0.01% 1334
2025
Q4 		$500K Buy
14,380
+647
+5% +$50.8K ﹤0.01% 1445
2025
Q3 		$1.14M Hold
13,733
– – ﹤0.01% 1016
2025
Q2 		$1.01M Buy
13,733
+307
+2% +$22.3K ﹤0.01% 1053
2025
Q1 		$1.53M Sell
13,426
-112
-0.8% -$6.82K ﹤0.01% 932
2024
Q4 		$682K Buy
13,538
+1,639
+14% +$85.9K ﹤0.01% 1247
2024
Q3 		$551K Buy
11,899
+1,462
+14% +$52K ﹤0.01% 1300
2024
Q2 		$339K Hold
10,437
– – ﹤0.01% 1461
2024
Q1 		$263K Hold
10,437
– – ﹤0.01% 1616
2023
Q4 		$339K Hold
10,437
– – ﹤0.01% 1471
2023
Q3 		$284K Buy
+10,437
New +$302K ﹤0.01% 1512

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pictet Asset Management's CORT Position: Q2 2026 in Review

Pictet Asset Management reduced its Corcept Therapeutics (CORT) stake by 5.6% in Q2 2026, selling an estimated $53K and leaving 14,812 shares worth $1.29M. The position accounts for ﹤0.01% of the portfolio, ranked #1053.

Pictet Asset Management first reported a position in CORT in Q3 2023 and has held it in 12 quarters since. The position peaked at $1.53M in Q1 2025. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Pictet Asset Management held 14,812 shares of Corcept Therapeutics worth $1.29M as of Q2 2026.
  • Pictet Asset Management sold 877 Corcept Therapeutics shares in Q2 2026, an estimated $53K.
  • Corcept Therapeutics made up ﹤0.01% of Pictet Asset Management's portfolio in Q2 2026, its #1053 holding.
  • Pictet Asset Management first reported a position in Corcept Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • Pictet Asset Management's Corcept Therapeutics position peaked at $1.53M in Q1 2025.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.